Multiparametric MRI of the prostate at 3 T: limited value of 3D (1)H-MR spectroscopy as a fourth parameter.

The aim of our study was to assess whether multiparametric magnetic resonance imaging (MP-MRI) of the prostate with three parameters (PS3: T2-weighted, DWI, and DCE) benefits from an additional fourth parameter (PS4: including (1)H-MRSI) in the detection and grading of prostate cancer (PCa) at 3 T.

MP-MRI was performed in 64 patients (mean 66. 7 years, mean PSA 13 ng/ml). Reference standard was obtained by histopathology. Two readers independently evaluated the images. A summation score of each individual parameter for three parameters (PS3) and for four parameters (PS4) was calculated.

In 52 (81. 3 %) of 64 patients, histopathology confirmed a PCa. The diagnostic performance for PCa detection of PS4 (O1: 91. 7 %, O2: 91. 3 %) equaled that of PS3 (O1: 92. 8 %, O2: 92. 2 %, P > 0. 05). Prediction of high-grade PCa by PS4 (O1: 75. 1 %, O2: 74. 7 %) was as good as with PS3 (O1: 75. 1 %, O2: 72. 8 %, P > 0. 05). Kappa agreement between the two readers was substantial (0. 734 PS4) to moderate (0. 558 PS3).

MP-MRI with four parameters including (1)H-MRSI does not increase the detection and grading of prostate cancer at 3 T compared to MP-MRI with three parameters. A sum score accurately detects PCa at 3 T without an endorectal coil and shows potential for the prediction of tumor grade.

World journal of urology. 2015 Sep 25 [Epub ahead of print]

Stephan H Polanec, Katja Pinker-Domenig, Peter Brader, Dietmar Georg, Shahrokh Shariat, Claudio Spick, Martin Susani, Thomas H Helbich, Pascal A Baltzer

Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna (AKH), Waehringer-Guertel 18-20, 1090, Vienna, Austria. , Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna (AKH), Waehringer-Guertel 18-20, 1090, Vienna, Austria. , Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna (AKH), Waehringer-Guertel 18-20, 1090, Vienna, Austria. , Division of Medical Radiation Physics, Department of Radiation Oncology, Medical University of Vienna (AKH), Waehringer-Guertel 18-20, 1090, Vienna, Austria. , Department of Urology, Medical University of Vienna (AKH), Waehringer-Guertel 18-20, 1090, Vienna, Austria. , Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna (AKH), Waehringer-Guertel 18-20, 1090, Vienna, Austria. , Clinical Institute of Pathology, Medical University of Vienna (AKH), Waehringer-Guertel 18-20, 1090, Vienna, Austria. , Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna (AKH), Waehringer-Guertel 18-20, 1090, Vienna, Austria. thomas. helbich@meduniwien. ac. at. , Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna (AKH), Waehringer-Guertel 18-20, 1090, Vienna, Austria. 

PubMed